Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Using Neurostimulation to Accelerate Change in Misophonia: a Pilot Study

NCT06333925 · View on ClinicalTrials.gov ↗

Study Summary

Misophonia, the inability to tolerate certain repetitive distressing sounds that are common, is gaining, recognition as an impairing condition. It is not a well-understood condition and there are no known treatments. The purpose of this study is to test a new misophonia intervention that uses emotion regulation strategies and different types of brain stimulation on misophonic distress. This study will examine changes in brain activity during presentation and regulation of misophonic versus distressing sounds. The study team plans to alter activity in a key area of the brain responsible for emotion regulation circuitry over 4 sessions with the goal to test if this intervention helps misophonic distress. Sixty adult participants with moderate to severe misophonia will be recruited and taught an emotion regulation skill and randomly assigned to receive one of two types of repetitive transcranial magnetic stimulation (rTMS). The study includes 9-10 visits: the remote screening visit(s), the initial MRI, the four neurostimulation sessions, the follow-up MRI, and two additional remote 1- and 3-month follow-up visits.

Interventions

  • DEVICE High Frequency Repetitive Transcranial Magnetic Stimulation (HF rTMS)
  • DEVICE Sham Repetitive Transcranial Magnetic Stimulation (sham- rTMS)
  • BEHAVIORAL Cognitive Restructuring

Study Locations (1)

North Carolina

  • Duke University Medical Center — Durham

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-05-14
Est. Completion 2026-11-30
Phase NA

Sponsor

Duke University

1,129 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06333925

The ClinicalTrials.gov registry entry for NCT06333925 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,129 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 6 conditions, with Anxiety Disorder appearing as the primary indexed condition, and to 3 interventions — of which High Frequency Repetitive Transcranial Magnetic Stimulation (HF rTMS) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06333925 reports 1 study location spanning 1 distinct geographic area — top geographies include North Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06333925 about?

NCT06333925 is a clinical study titled "Using Neurostimulation to Accelerate Change in Misophonia: a Pilot Study". Misophonia, the inability to tolerate certain repetitive distressing sounds that are common, is gaining, recognition as an impairing condition. It is not a well-understood condition and there are no known treatments. The purpose of this study is to test a new misophonia intervention that uses emotio...

What is the current status of trial NCT06333925?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2024-05-14. Estimated completion is 2026-11-30.

What conditions does trial NCT06333925 study?

This clinical trial studies the following conditions: Anxiety Disorder, Misophonia, Sensory Processing Disorder, Emotion Dysregulation, Auditory Over Responsivity. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06333925?

The interventions under investigation include: High Frequency Repetitive Transcranial Magnetic Stimulation (HF rTMS) (DEVICE), Sham Repetitive Transcranial Magnetic Stimulation (sham- rTMS) (DEVICE), Cognitive Restructuring (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06333925?

This trial is sponsored by Duke University, which has 1,129 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06333925 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial